About Faeth Therapeutics, Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.senseibio.com
Frequently Asked Questions
What is the 52-week range for FTH?
The 52-week high is $42.1431 and the 52-week low is $13.43.
What is the P/E ratio for FTH?
The P/E ratio data is currently unavailable.
What is the dividend yield for FTH?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -189.59%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Analyst Recommendation Trends
Wall Street analyst consensus for FTH over the last few months:
Latest FTH News
Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion
Initiate Faeth Therapeutics (FTH) at Buy: PIKTOR cancer program catalysts through 2027, $200M raise boosts runway but dilution risk.
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
AUSTIN, Texas, September 17, 2026--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways, today announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026.
Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70
Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.
LUCID CAPITAL MARKETS Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $59
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $59.
TD Cowen Initiates Coverage On Faeth Therapeutics with Buy Rating
TD Cowen analyst Tara Bancroft initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating.
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
AUSTIN, Texas, September 08, 2026--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 6, 2026 at 10:00 AM ET featuring Marcus Goncalves, MD, PhD (NYU Langone Health & Scientific Co-founder, Faeth Therapeutics), who will join company management to discuss the PAM (PI3K/AKT/mTOR) pathway in human canc
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-11 | Vousden Karen H | +25,000 | - | - |
| 2026-07-21 | Parikh Anand Kiran | +398,018 | - | - |
| 2026-07-21 | Craver Josiah | +30,824 | - | - |
| 2026-07-01 | STEPHENSON BRIAN C | +600 | $24.22 | $14,532 |
| 2026-07-01 | STEPHENSON BRIAN C | +4,400 | $23.4 | $102,960 |
| 2026-06-30 | STEPHENSON BRIAN C | +4,255 | $24.98 | $106,290 |
| 2026-06-30 | STEPHENSON BRIAN C | +1,638 | $23.88 | $39,115 |
| 2026-06-30 | STEPHENSON BRIAN C | +1,910 | $22.95 | $43,835 |
| 2026-06-29 | STEPHENSON BRIAN C | +831 | $23.34 | $19,396 |